The Readout Loud
Episode 200: Gilead's growing pains, Covid's origins, & Theranos as prestige TV
This episode isn’t summarized yet
Create a free account and summarize it. In a few minutes you’ll have the key takeaways and a section-by-section summary.
Show notes
Can biotech companies age gracefully? Where did Covid-19 come from? And does Theranos make for good television?
We cover all that and more this week. We examine Gilead Sciences' recent struggles and what the company's predicament says about the drug industry. Then, MIT Technology Review reporter Antonio Regalado joins us to discuss his new podcast investigating the origins of Covid-19. We also discuss the latest Theranos trial, playing Elizabeth Holmes on TV, and how we managed to make 200 episodes of this show.